Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SHRA-2102 by Jiangsu Hengrui Medicine for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
SHRA-2102 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Squamous Non-Small Cell Lung Cancer....
Data Insights
SHRA-2102 by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval
SHRA-2102 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to GlobalData,...